Brief: Reviva Announces Canadian Composition Of Matter Patent For RP1208
21/11/2022 11:49
Nov 21 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
RVPH.O :
* REVIVA PHARMACEUTICALS ANNOUNCES CANADIAN COMPOSITION OF
MATTER
PATENT FOR TRIPLE REUPTAKE INHIBITOR RP1208
* REVIVA PHARMACEUTICALS HOLDINGS, INC. - LOOK FORWARD TO
ADVANCING PRECLINICAL DEVELOPMENT OF RP1208 THROUGH IND-ENABLING
STUDIES
Source text for Eikon: ID:nGNXq4wcq
Further company coverage: RVPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Reviva Pharmaceuticals Holdings
See all newsReviva Pharmaceuticals Q1 net loss narrows on lower expenses
Brief: Reviva Pharmaceuticals Holdings Inc - To Be Delisted From Nasdaq Trading Suspended As Of May 14, 2026 - SEC Filing
Brief: Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending
U.S. STOCKS ON THE MOVE-Darden Restaurants, Mastercard, Accenture